Three doses of BNT162b2 COVID-19 mRNA vaccine establish long-lasting CD8<sup>+</sup> T cell immunity in CLL and MDS patients.

导出 LinkOut

翻译打印收藏纠错

第一作者： Susana Patricia Amaya,Hernandez

第一单位： Department of Health Technology, Section of Experimental and Translational Immunology, Technical University of Denmark, Kongens Lyngby, Denmark.

作者： Susana Patricia Amaya,Hernandez ^[1] ; Ditte Stampe,Hersby ^[2] ; Kamilla Kjærgaard,Munk ^[1] ; Tripti,Tamhane ^[1] ; Darya,Trubach ^[1] ; Maria,Tagliamonte ^[3] ; Luigi,Buonaguro ^[3] ; Anne Ortved,Gang ^[2] ; Sine Reker,Hadrup ^[1] ; Sunil Kumar,Saini ^[1]

作者单位： Department of Health Technology, Section of Experimental and Translational Immunology, Technical University of Denmark, Kongens Lyngby, Denmark. ^[1] Department of Hematology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. ^[2] Innovative Immunological Models Unit, National Cancer Institute Pascale Foundation - IRCCS, Napoli, Italy. ^[3]

关键词 CD8+ T cell Hematological cancer SARS – CoV – 2 T cell memory T-cell immunity mRNA vaccine against SARS-CoV-2

主题词人类(Humans);CD8阳性T淋巴细胞(CD8-Positive T-Lymphocytes);白血病, 淋巴细胞, 慢性, B细胞(Leukemia, Lymphocytic, Chronic, B-Cell);骨髓增生异常综合征(Myelodysplastic Syndromes)

DOI 10.3389/fimmu.2022.1035344

PMID 36703960

发布时间 2023-02-02

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交